Haemonetics (HAE) vs Merit Medical Systems (MMSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Haemonetics (HAE) has outperformed Merit Medical Systems (MMSI) over the past year, gaining 134.3% versus a gain of 1.8%. Over five years, HAE leads with a +45.5% price change compared with +22.5% for MMSI. Haemonetics is the larger company by market cap ($5.44 billion vs $5.09 billion), about 1.1 times the size, while Merit Medical Systems is growing revenue faster (+11.8% vs -2.0%).
On valuation, Merit Medical Systems trades at a lower forward P/E (18.5x vs 20.7x for Haemonetics). Merit Medical Systems converts more of its revenue into profit, with a net margin of 8.5% versus 7.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | MMSI |
|---|---|---|
| Share price | $119.47 | $85.25 |
| Market cap | $5.44B | $5.09B |
| 1-day change | +17.46% | +0.19% |
| YTD return | +49.06% | -3.28% |
| 1-year return | +134.35% | +1.80% |
| 5-year return | +45.49% | +22.50% |
| P/E ratio (TTM) | 57.71 | 35.08 |
| Forward P/E | 20.68 | 18.49 |
| EPS (TTM) | $2.07 | $2.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $1.52B |
| Revenue growth (YoY) | -1.97% | +11.75% |
| Net income (latest FY) | $97.31M | $128.49M |
| Gross margin | 59.04% | 48.70% |
| Operating margin | 11.75% | 12.19% |
| Net margin | 7.29% | 8.48% |
| 52-week high | $120.72 | $94.75 |
| 52-week low | $48.17 | $59.74 |
| Distance from 52-week high | -1.04% | -10.03% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -6.67% | +19.00% |
| Average volume | 678.94K | 795.56K |
| Shares outstanding | 45.50M | 59.71M |
| Employees | 3,009 | 7,500 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed MMSI by 132.5 percentage points over the past year.
- Haemonetics trades at a higher earnings multiple (57.7x vs 35.1x trailing P/E).
- Merit Medical Systems grew revenue faster in its latest fiscal year (+11.75% vs -1.97%).
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About Merit Medical Systems
MMSI stock →Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally.
Health Care · Medical/Dental Instruments · 7,500 employees
HAE vs MMSI FAQ
Which is bigger, Haemonetics or Merit Medical Systems?
Haemonetics (HAE) is larger, with a market capitalization of $5.44B compared with $5.09B for Merit Medical Systems (MMSI).
Which stock has performed better over the past year, HAE or MMSI?
HAE returned +134.35% over the past 12 months, compared with +1.80% for MMSI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HAE or MMSI?
MMSI has the lower trailing P/E at 35.1, versus 57.7 for HAE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Haemonetics and Merit Medical Systems in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.